Blacklock's Reporter

Spending on prescription medicines by public insurers rose a “considerable” 7.4 percent last year compared to 1.7 percent in 2017, a federal agency reported yesterday. The Patented Medicine Prices Review Board found only “limited savings” from use of generic drugs: “Notable growth in 2018 was primarily driven by increases in the patented medicine market.”